Antibodies to Watch in 2021: Anti-SARS-CoV-2 targeted therapies to the rescue
The COVID-19 pandemic has presented many challenges to the biopharmaceutical industry. Initiating programs to discover and develop new antibodies that targeted SARS-CoV-2 was critical, but at the same time, programs bringing existing investigational therapies through late-stage clinical studies and regulatory review also needed to be maintained.
In this webinar, Dr. Janice Reichert (The Antibody Society) provides an update on antibody therapeutics approved in the US and European Union during 2020, those that may be approved by the end of 2021, and those that might enter regulatory review in the US or EU soon. She will also discuss current and potential emergency use authorizations for anti-SARS-CoV-2 antibodies.
Additionally, Dr. Nick Hutchinson (FUJIFILM Diosynth Biotechnologies) discusses how the pandemic has driven scientists and engineers to find new ways to leverage antibody production capacity most effectively in order to meet the need for rapid early phase development, as well as high-demand commercial manufacturing and what this may mean for antibody manufacturing strategies in the future.
Speakers: Dr. Janice Reichert and Dr. Nick Hutchinson
Broadcast date: December 3, 2020
Antibodies to Watch in a Pandemic
The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe have mobilized teams to research the SARS-CoV-2 virus and COVID-19, conduct clinical studies of repurposed biologics, and research and develop anti-SARS-CoV-2 biologics. Disruptions at companies and regulatory agencies, however, have raised concerns about the effects of the pandemic on possible approvals of non-COVID-19 antibody therapeutics.
In this webinar, Dr. Janice Reichert (The Antibody Society) provides an update on non-COVID-19 antibody therapeutics approved as of June 2020, and those that might be approved by the end of the year. She also discusses the ~ 130 biologics currently in commercial development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics.
Additionally, Dr. Thomas Schirrmann (YUMAB) presents a case study of an academic and industrial consortium for the fast-track development of a SARS-CoV-2 antibody therapy. He highlights the challenges of discovering and developing an antibody drug during the present pandemic.
Speakers: Dr. Thomas Schirrmann and Dr. Janice Reichert
Broadcast date: June 30, 2020